trientine has been researched along with Cardiomyopathy, Hypertrophic in 2 studies
Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.
TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.
2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.
Cardiomyopathy, Hypertrophic: A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trientine is a highly selective copper II chelator." | 3.30 | Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy. ( Akhtar, M; Ashkir, Z; Baroja, O; Bedson, E; Clayton, D; Cooper, RM; Dodd, S; Duran, B; Farrant, J; Garratt, C; Harrington, C; Mahmod, M; Miller, CA; Naish, JH; Neubauer, S; Prasad, SK; Raman, B; Reid, A; Schmitt, M; Singh, A; Spowart, C; Valkovič, L; Vaughan, C, 2023) |
| "Trientine treatment was safe and tolerated." | 1.72 | Copper chelation in patients with hypertrophic cardiomyopathy. ( Clark, D; Cooper, G; Farrant, JP; Miller, C; Polturi, R; Ray, S; Reid, A; Schmitt, M, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reid, A | 2 |
| Miller, C | 1 |
| Farrant, JP | 1 |
| Polturi, R | 1 |
| Clark, D | 1 |
| Ray, S | 1 |
| Cooper, G | 1 |
| Schmitt, M | 2 |
| Farrant, J | 1 |
| Dodd, S | 1 |
| Vaughan, C | 1 |
| Garratt, C | 1 |
| Akhtar, M | 1 |
| Mahmod, M | 1 |
| Neubauer, S | 1 |
| Cooper, RM | 1 |
| Prasad, SK | 1 |
| Singh, A | 1 |
| Valkovič, L | 1 |
| Raman, B | 1 |
| Ashkir, Z | 1 |
| Clayton, D | 1 |
| Baroja, O | 1 |
| Duran, B | 1 |
| Spowart, C | 1 |
| Bedson, E | 1 |
| Naish, JH | 1 |
| Harrington, C | 1 |
| Miller, CA | 1 |
1 trial available for trientine and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy.
Topics: Cardiomyopathy, Hypertrophic; Copper; Fibrosis; Heart; Humans; Hypertrophy, Left Ventricular; Trient | 2023 |
1 other study available for trientine and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Copper chelation in patients with hypertrophic cardiomyopathy.
Topics: Biological Availability; Cardiomyopathy, Hypertrophic; Chelating Agents; Copper; Drug Monitoring; Ex | 2022 |